These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32449261)

  • 21. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 23. Is having more preapproval data the best way to assure drug safety?
    Garber AM
    Health Aff (Millwood); 2008; 27(5):w371-3. PubMed ID: 18682442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012.
    Crossley JR; Tan TP; Smith KH; Ross JS; Merenstein DJ
    J Gen Intern Med; 2018 Sep; 33(9):1431-1432. PubMed ID: 29777429
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

  • 26. Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis.
    Zeitoun JD; Ross JS; Atal I; Vivot A; Downing NS; Baron G; Ravaud P
    Clin Pharmacol Ther; 2018 Nov; 104(5):1000-1007. PubMed ID: 29377075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A beneficial side effect of the Medicare drug benefit.
    Platt R; Ommaya A
    N Engl J Med; 2005 Dec; 353(26):2742-3. PubMed ID: 16382059
    [No Abstract]   [Full Text] [Related]  

  • 28. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 29. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 30. A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System.
    Cocoros NM; Fuller CC; Adimadhyam S; Ball R; Brown JS; Dal Pan GJ; Kluberg SA; Lo Re V; Maro JC; Nguyen M; Orr R; Paraoan D; Perlin J; Poland RE; Driscoll MR; Sands K; Toh S; Yih WK; Platt R;
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):827-837. PubMed ID: 33797815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. After Avandia, some seek split in drug approval and monitoring.
    Dolgin E
    Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug-safety pilot makes the grade.
    Ledford H
    Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
    [No Abstract]   [Full Text] [Related]  

  • 33. The Vioxx debacle.
    Fielder JH
    IEEE Eng Med Biol Mag; 2005; 24(2):106-9. PubMed ID: 15825852
    [No Abstract]   [Full Text] [Related]  

  • 34. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
    Allan MC
    J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-market approval surveillance: a call for a more integrated and comprehensive approach.
    Mehran R; Leon MB; Feigal DA; Jefferys D; Simons M; Chronos N; Fogarty TJ; Kuntz RE; Baim DS; Kaplan AV
    Circulation; 2004 Jun; 109(25):3073-7. PubMed ID: 15226222
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.
    Fan Y; Sun B; Agarwal S; Zhang L
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S193-204. PubMed ID: 27385175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preventing postmarketing changes in recommended doses and marketing withdrawals.
    Peck C
    Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.